TLDR
- ABCL stock rose 6.13%, with an earlier intraday jump of 10.3% to $6.53 following Q2 earnings and pipeline news
- Top-line Phase 2 results for ABCL635, a non-hormonal menopause treatment, will be released before market open on August 10
- Q2 revenue fell 76.3% year-over-year to $4.05 million, while net loss widened to $55.4 million
- The company holds $567 million in cash and over $675 million in available liquidity
- Partnerships with Jazz and Vertex have brought in more than $110 million in upfront cash
AbCellera Biologics (ABCL) jumped as much as 10.3% to $6.53 on August 7, closing up 6.13%, as investors reacted to Q2 earnings and an upcoming clinical data release.
AbCellera Biologics Inc., ABCL
The company announced it will release top-line Phase 2 results for ABCL635 before market open on August 10, 2026. An investor call and webcast are scheduled for 4:30 a.m. PT that morning.
ABCL635 is a potential first-in-class non-hormonal antibody targeting the NK3 receptor, designed to reduce the frequency and severity of vasomotor symptoms in postmenopausal women. It entered the clinic in July 2025.
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 https://t.co/iKiCXMLGZe pic.twitter.com/haJhACRwFq
— AbCellera (@AbCelleraBio) August 7, 2026
The Phase 2 trial enrolled approximately 80 postmenopausal women in a randomized, double-blind, placebo-controlled design. It carries the trial identifier NCT07118891.
The data release is the first Phase 2 readout from AbCellera’s GPCR and ion channel platform, making it a closely watched milestone for the company.
Q2 Numbers Tell a Different Story
Q2 financials were weak. Revenue came in at $4.05 million, down 76.3% from $17.08 million in Q2 2025. The net loss widened 59.7% to $55.4 million.
Basic EPS was a loss of $0.18 per share, compared to a loss of $0.12 per share a year ago. Research and development spending reached approximately $46 million in the quarter.
The pipeline did advance. AbCellera now has nine products in Phase 1 and one in Phase 2, compared to 11 in Phase 1 and none in Phase 2 a year ago.
ABCL575 completed Phase 1 dosing, with a readout expected in Q4 2026.
Cash Position Cushions the Burn
Despite the losses, the balance sheet remains a key argument for bulls. The company ended the quarter with $567 million in cash and more than $675 million in total available liquidity.
Partnerships with Jazz Pharmaceuticals and Vertex, focused on T cell engager programs, contributed more than $110 million in upfront cash payments.
Critics note that these are one-time deal payments rather than recurring revenue. Milestones and royalties have not yet scaled to offset ongoing losses.
The most recent analyst rating on ABCL is a Buy, with a $12.00 price target. The stock’s current market cap sits at approximately $1.74 billion.
All eyes now turn to the August 10 data release for ABCL635.
